- Home
- IXHL
IXHL
Incannex Healthcare Inc.
as 04-23-2025 4:00pm EST
Stocks
| Founded: | 2001 | Country: | Australia |
| Employees: | N/A | City: | DOCKLANDS, VICTORIA |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 317.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $3.55 | Next Earning Date: | 05-14-2025 |
| Revenue: | $98,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 3817.05% | Revenue Growth (next year): | 66.67% |
Latest Incannex Healthcare Inc. News
IXHL Breaking Stock News: Dive into IXHL Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 days ago
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
GlobeNewswire
2 months ago
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
Newsfile
2 months ago
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025
GlobeNewswire
2 months ago
Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire
3 months ago
Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board
GlobeNewswire
3 months ago
Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea
Newsfile
5 months ago
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025
GlobeNewswire
5 months ago
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
Compare IXHL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IXHL Incannex Healthcare Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.